| Detailed information |
|---|
| CancerLivER ID | 2239 |
| Biomarker | lncCAMTA1 |
| Biomarker Name/Symbol (given in Publication) | lncCAMTA1 |
| Biomolecule | LncRNA |
| Subject | Human |
| Degree of Validity | lncCAMTA1 could be an effective prognostic factor and a potential therapeutic target for HCC; but not validated on independent dataset |
| Experimental Condition | HCC v/s Normal; associated with poor recurrence free survival and overall survival of patients |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Upregulated in HCC and lncCAMTA1 is increased in HCC and indicates poor outcome. |
| Level of significance | p < 0.01 |
| Source | Tissue |
| PMID | 27669232 |
| Type of Biomarker | Prognostic |
| Pathway | NA |
| Cohort | 90 pairs of fresh HCC tissues and paired adjacent non-cancerous hepatic tissues; Normal human liver cell lines L02 and QSG-7701, and human HCC cell lines SMMC-7721, HCCLM3, HepG2, Hep3B, and Huh7 |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | Human HCC |
| Year of Publication | 2016 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |